Analyst Price Targets — MGNX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 20, 2026 9:24 am | — | Barclays | $6.00 | $3.46 | TheFly | MacroGenics price target raised to $6 from $4 at Barclays |
| May 14, 2025 9:31 am | Peter Lawson | Barclays | $3.00 | $1.59 | TheFly | MacroGenics price target lowered to $3 from $8 at Barclays |
| March 25, 2025 10:05 am | — | H.C. Wainwright | $2.00 | $1.79 | TheFly | MacroGenics price target lowered to $2 from $4 at H.C. Wainwright |
| August 7, 2024 10:18 am | Stephen Willey | Stifel Nicolaus | $6.00 | $3.38 | StreetInsider | MacroGenics (MGNX) PT Lowered to $6 at Stifel |
| July 31, 2024 6:33 am | Silvan Tuerkcan | JMP Securities | $8.00 | $5.25 | TheFly | MacroGenics price target lowered to $8 from $16 at JMP Securities |
| July 31, 2024 3:21 am | Mayank Mamtani | B.Riley Financial | $5.00 | $5.25 | StreetInsider | B.Riley Downgrades MacroGenics (MGNX) to Neutral |
| July 29, 2024 5:41 am | Peter Lawson | Barclays | $9.00 | $5.55 | TheFly | MacroGenics price target lowered to $9 from $14 at Barclays |
| May 23, 2024 6:39 pm | Kaveri Pohlman | BTIG | $9.00 | $4.63 | TheFly | MacroGenics price target lowered to $9 from $24 at BTIG |
| May 13, 2024 7:17 am | Debjit Chattopadhyay | H.C. Wainwright | $4.00 | $4.38 | StreetInsider | MacroGenics (MGNX) PT Lowered to $4 at H.C. Wainwright |
| May 10, 2024 5:23 am | Peter Lawson | Barclays | $14.00 | $14.67 | TheFly | MacroGenics price target lowered to $14 from $25 at Barclays |
Latest News for MGNX
• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers • On track to provide mid-2026 program update ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the U. S. Food and Drug Administration (FDA)…
Medtronic (NYSE: MDT - Get Free Report) and MacroGenics (NASDAQ: MGNX - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations. Profitability This table compares Medtronic and MacroGenics' net margins, return
MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
MacroGenics (MGNX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.25 per share a year ago.
ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress, reported financial results for the year ended December 31, 2025, and highlighted anticipated data disclosure timelines for its product…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MGNX.
U.S. House Trading
No House trades found for MGNX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.